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Purpose of review
To examine the role of gut microbiota in the regulation of host energy homeostasis and
its role in the pathogenesis of obesity, diabetes and nonalcoholic fatty liver disease
(NAFLD)
Recent findings
Experimental models highlight several mechanisms connecting gut microbiota to host
energy metabolism: increased energy harvesting from the diet, regulation of appetite
through gut peptide, secretion, regulation of tissue-free fatty acid composition and
uptake, storage and oxidation, modulation of intestinal barrier by glucagon-like peptide-
2 secretion, activation of innate immunity and hepatic fibrogenesis through the
lipopolysaccharide (LPS)–toll-like receptor-4 axis.
Gut microbiota manipulation through antibiotics, prebiotics and probiotics yields
encouraging results for the treatment of obesity, diabetes and NAFLD in animal models,
but data in humans are currently scarce.
Summary
Gut microbiota manipulation yielded encouraging results for the treatment
of different metabolic disorders in experimental models. However, changing
intestinal microbiota may be more difficult in free-living individuals compared to
standardized laboratory models, and its long-term consequences are unknown.
To safely and effectively change human gut microflora, future research should
highlight the complex hormonal, immunomodulatory and metabolic mechanisms
underlying microbiota–host interactions in different tissues and candidate
treatments should be evaluated in well designed trials with patient-oriented
end-points.
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0957-9672Introduction
Growing evidence demonstrates that the normal gut
microbiome contributes to the development of diet-
induced obesity. The human gut hosts 100 trillion micro-
organisms, encompassing hundreds of species. Colonic
density of bacterial cells is estimated to be 1012 per ml,
making the colon one of the most densely populated
microbial habitats on Earth. The genome size of this
microbial organ, collectively named ‘microbiome’,
exceeds the size of the human nuclear genome by two
orders of magnitude, providing the host with important
biological functions. Recent research has highlighted some
key aspects of the mammalian host–gut microbial relation-
ship that could link gut microbiome to human obesity.
We will review advances in understanding the role of
gut microbiota in the pathogenesis of obesity, diabetes,opyright © Lippincott Williams & Wilkins. Unautho
0957-9672  2010 Wolters Kluwer Health | Lippincott Williams & Wilkinsnonalcoholic fatty liver disease (NAFLD) and their poten-
tial therapeutic applications.Role of gut microbiota in the regulation of fat
storage
The involvement of gut microbiota in the regulation of
host energy homeostasis has been first suggested by the
pioneer experiments of J. Gordon’s group: they noticed
that germ-free (i.e. raised in the absence of microorgan-
isms) mice had 40% less total body fat than mice with a
normal gut microbiota, even though the latter ate 30%
less calories than did the germ-free animals [1]. If germ-
free mice were ‘conventionalized’ with gut microbiota
harvested from the cecum of a ‘normal’ mouse, they
gained a 60% increase in body fat and insulin resistance
within 2 weeks, despite a significant lower food intake.rized reproduction of this article is prohibited.
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Figure 1 Proposed mechanisms of the effects of gut microbiota on host metabolic and inflammatory processes
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lysaccharide; TLR-4, toll-like receptor 4.Subsequent research tried to elucidate the factors regulat-
ing gut microbiota composition and how it interacts with
the host organism to influence the development of obesity
and associated metabolic disorders. Mechanisms poten-
tially underlying the weight gain under excessive caloric
intake include an increase in the intestinal glucose absorp-
tion and energy extraction from nondigestible food com-
ponent and concomitant higher glycemia and insulinemia.
Glucose and insulin are known to promote hepatic de-novo
lipogenesis through the expression of two key lipogenic
enzymes, that is acetyl-CoA carboxylase (ACC) and
fatty acid synthase (FAS). Consistently, a 2-week con-
ventionalization of germ-free mice was associated with a
two-fold increase in hepatic triglyceride content, accom-
panied by an increased hepatic mRNA expression of
sterol-responsive element-binding protein (SREBP-1)
and carbohydrate-responsive element-binding protein
(ChREBP), two nuclear positive regulators of lipogenic
enzymes [1,2]. Furthermore, conventionalized mice had a
higher monosaccharide uptake from the intestine to the
portal blood, at least partly explained by the digestion of
polysaccharides by microbial enzymes and by the higheropyright © Lippincott Williams & Wilkins. Unauthcapillary density of the small intestine of conventionalized
mice as compared to their germ-free counterparts. Lastly,
the conventionalization also induced a systemic increase in
lipoprotein lipase (LPL) activity, the enzyme catalyzing
the release of free fatty acids (FFAs) and triacylglycerol
from circulating triglyceride-rich lipoproteins to adipose
tissue and muscle. The authors proposed that such an
increase was the consequence of suppression of the
fasting-induced adipose factor (FIAF) in the gut. FIAF
inhibits the LPL activity (Fig. 1). The blunted FIAF
expression in conventionalized germ-free mice might con-
tribute to triacylglycerol accumulation in adipocytes and
adipose tissue hypertrophy of conventionalized mice. This
set of experiments demonstrated for the first time that an
environmental factor such as gut microbiota may regulate
energy storage.Association between gut microbiota
composition and obesity
The demonstration that obesity is accompanied by an
altered microbiota composition in animals and humansorized reproduction of this article is prohibited.
C78 Nutrition and metabolismcame subsequently from the same group [3,4]: upon
characterization of over 5000 gut bacterial 16S RNA gene
sequences, they found that genetically obese ob/ob mice
had a 50% reduction in abundance of Bacteroidetes and a
proportional increase in Firmicutes compared to their
lean counterparts. In a parallel way, obese people were
shown to have lower Bacteroidetes and more Firmicutes
in their distal gut than did lean control individuals,
alterations that were abolished after 52 weeks of diet-
induced weight loss. To definitively assess if such differ-
ent gut bacterial composition regulates body fat content,
Turnbaugh et al. [5] transplanted cecal microbiota from
lean and ob/ob mice to germ-free wild-type animals: after
2 weeks, rodents hosting the microbiota from obese mice
increased their fat mass, and extracted more calories from
food than the lean mice hosting the gut microbiota from
lean mouse donors. Metagenomic analysis of the high-fat
fed gut microbiome showed an increase in glycoside
hydrolases, capable of breaking down otherwise indiges-
tible alimentary polysaccharides, in transport proteins
and enzymes involved in import and fermentation of
simple sugars and host glycans, which can be utilized
by the host for hepatic lipogenesis. As a consequence,
hosts have an increased capacity to harvest energy from
their diet.Dietary fat determines the composition of the
gut microbiome independently of obesity
To address whether the differences in gut microbiota
composition between high fat-fed obese phenotype and
lean phenotype [6] derive from the obese state or directly
from the effects of different diet composition on bacterial
populations, Hildebrandt et al. [7] employed the RELMb
knockout mice, a phenotype that is resistant to high-fat-
induced obesity. When RELMb knockout and RELMb
wild-type mice were switched from a standard chow diet to
a high-fat diet, the changes in the composition of the gut
microbiome (expansion of the Firmicutes at the expense of
the Bacteriodetes phylum) were similar between wild-
type and knockout mice, indicating that effects of diet
dominated. These findings were replicated by other
groups ([6,9,36]) and indicate a high-fat diet, and not
the obese state, can modulate microbiota composition
by driving an increase in Firmicutes and a proportional
decrease in Bacteroidetes.Gut microbiota modulates the development
of high-fat diet-induced obesity and insulin
resistance
A further key experiment subsequently demonstrated
that gut microbiota is an essential mediator of diet-
induced metabolic disorders: Backhed et al. [8] fed
germ-free or conventionalized mice a western diet (high
fat/high carbohydrates). At the end of the experiment,opyright © Lippincott Williams & Wilkins. Unauthogerm-free mice gained significantly less weight and fat
mass than conventionalized mice, and were protected
against the high-fat diet induced by glucose intolerance
and insulin resistance. Differently from previous experi-
ments, germ-free and conventionalized mice had a
similar energy content in their feces, suggesting a more
efficient energy harvesting from the high-fat diet which
may not be the sole factor responsible for the fat
mass gain of the conventionalized mice. The authors
proposed two independent mechanisms, both resulting
in increased FFA metabolism, at the basis of the resist-
ance of germ-free mice to diet-induced obesity: elevated
circulating levels of FIAF, which inhibits tissue LPL
and increases expression of the peroxisomal proliferator-
activated receptor coactivator (PGC)-1a, a key regulator
of enzymes involved in fatty acid oxidation; increased
muscle and liver activity of the enzyme AMP-activated
protein kinase (AMPK), which activates key enzymes of
mitochondrial fatty acid oxidation, namely acetyl-CoA
carboxylase and carnitinepalmitoyltransferase.
Thus, these data suggest that a bacterially related factor/
mechanism other than energy harvesting may be respon-
sible for the development of diet-induced obesity and
diabetes.Gut microbiota contributes to the low-grade
inflammatory state of obesity
Gut microbiota has been recently linked to the low-grade
chronic inflammatory grade which characterizes western
diet-induced metabolic disorders. Specifically, the bac-
terial LPS, a cell-wall component of Gram-negative
bacteria, could link gut microbiota to inflammation in
obesity, diabetes, NAFLD, cardiovascular disease [9].
LPS is largely abundant in enteric Gram-negative flora
and triggers the inflammatory process by binding to the
complex of CD14 and the toll-like receptor-4 (TLR4) at
the surface of innate immune cells [10]. More specifi-
cally, CD14 is a multifunctional receptor constituted by
a phosphatidyl inositol phosphate anchored glycoprotein
of 55 kDa expressed on the surface of monocytes, macro-
phages and neutrophils.
Cani et al. [6,11] demonstrated that after 2–4 weeks of
high-fat feeding the mice exhibited a significant increase
in circulating LPS levels, which they called ‘metabolic
endotoxemia’, as LPS plasma concentrations were much
lower than those commonly observed during septic
shock. To assess the role of LPS as a trigger for the
development of obesity and metabolic disorders, they
reproduced the metabolic endotoxemia by chronically
infusing mice with a very low dose of LPS to reach plasma
LPS levels similar to those observed in the high-fat diet-
fed mice [6]. After 4 weeks, LPS-infused animals devel-
oped the same phenotype as those on a high-fat diet,rized reproduction of this article is prohibited.
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tosis and insulin resistance, and adipose tissue macro-
phages infiltration. Finally, they challenged LPS receptor
knockout (CD14KO) mice with a high-fat diet and, on a
separate experiment, with a chronic low-dose LPS infu-
sion. As expected, CD14KO mice were completely resist-
ant to the development of insulin resistance and inflam-
mation in the visceral and subcutaneous adipose depots,
the liver and the muscle induced by both high-fat feed-
ing or chronic low-dose LPS administration. Moreover,
CD14KO mice were hypersensitive to insulin, even when
they are fed a normal diet, suggesting that CD14 could be a
modulator of insulin sensitivity in physiological conditions.
Taken together, these data support the concept that gut
microbiota can play a key role in the pathogenesis of
obesity-associated metabolic disorders.Gut microbiota in the pathogenesis of
nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease is considered the hepatic
manifestation of metabolic syndrome and obesity. It
encompassess a spectrum ranging from simple steatosis
to nonalcoholic steatohepatitis (NASH) – the latter
potentially evolving to advanced fibrosis, cirrhosis and
end-stage liver disease [12]. Therefore, most of the
current research in the field focuses on mechanisms
leading to hepatic inflammation and fibrogenesis.
Different lines of evidence suggest gut bacteria may
contribute to the pathogenesis of NAFLD. Plasma endo-
toxin levels are significantly higher in patients with
NAFLD of different histological severity, from simple
steatosis to NASH and fibrosis, and are associated with
small intestinal bacterial overgrowth, increased intestinal
permeability and with an induction of the endotoxin
receptor TLR4 in the liver [13–15,16]. Circulating
levels of lipopolysaccharide-binding protein (LBP) have
been found to be increased in patients with NAFLD and
to a higher extent in patients with the progressive form
of NAFLD, that is NASH, closely correlating with the
increased hepatic expression of TNF-a [17]. The role of
LPS-TLR4 axis in the pathogenesis of NASH was further
substantiated by the observation that the functional
deletion of TLR4 axis protected methionine-choline-
deficient (MCD) diet-fed mice from the development
of NASH [18].
The pathogenesis of increased intestinal permeability
associated with bacterial overgrowth is not completely
understood. Animal and human models of NASH suggest
that bacterial metabolism of pyruvate, which is produced
during the breakdown of carbohydrates, generates meta-
bolites, including acetaldehyde and ethanol, toxic for the
intestinal epithelium, leading to a disruption of the tightopyright © Lippincott Williams & Wilkins. Unauthjunctions [19,20]. Consistent with these findings, an
excessive dietary fructose intake has been recently
associated with the development of NAFLD in epide-
miological studies, even in the absence of obesity, dia-
betes or other traditional risk factors [21,22]. To examine
the interaction between fructose intake and LPS-TLR4-
mediated hepatic steatosis, Spruss et al. [23] fed TLR4-
mutant mice and wild-type mice with fructose or plain
water for 8 weeks. Chronic fructose intake caused a
significant increase in hepatic steatosis, lipoperoxidation
and insulin resistance, coupled with a 22-fold increased
hepatic expression of TNF-a and a 27-fold increase in
portal endotoxin levels, in wild-type animals in comparison
to water controls. All these alterations, except increased
portal endotoxin levels, were significantly decreased in
fructose-fed TLR4-mutant mice, suggesting LPS-TLR4
axis mediates the deleterious effects of excessive fructose
intake on the liver. In line with this observation, the
treatment with intestinal nonabsorbable antibiotics signifi-
cantly reduced portal endotoxin levels, hepatic TNF-a
expression, steatosis and liver injury in fructose-induced
NAFLD animal models [24].
Apart from hepatic steatosis and inflammation, and most
relevant for the hepatic complications of NAFLD, gut-
derived LPS has also been directly connected to hepatic
fibrogenesis via TLR4-mediated activation of hepatic
stellate cells [25]. By challenging TLR4-knockout
(TRL4-KO) mice with LPS, Seki et al. [25] showed that
LPS directly activates hepatic stellate cells via a TLR4-
dependent pathway. LPS enhances stellate cell acti-
vation by transforming growth factor (TGF)-b through
down-regulation of the membrane receptor Bambi, a
TGF-b pseudoreceptor with negative regulatory func-
tion. Activated hepatic stellate secrete chemotactic
agents, including Ccl2 and Ccl4, to recruit Kuppfer cells,
which in turn secrete profibrogenic TGF-b, thus perpe-
tuating the cycle (Fig. 2). Consistent with this model, the
treatment with the probiotic VSL#3 led to upregulation
of Bambi and ameliorated liver fibrosis in the methion-
ine-choline-deficient (MCD) diet-induced mouse model
of NASH [26].
Collectively, these experiments suggest that gut micro-
biota manipulation can help counteract the impact of
unbalanced diets on the liver and may usefully add to
other therapeutic options for NAFLD.Gut microbiota as a modulator of cellular fatty
acid membrane composition
An emerging mechanism whereby gut flora manipulation
can affect host metabolism and fat storage is the modu-
lation of fatty acid composition of host cellular mem-
branes: different gut bacteria species produce bioactive
isomers of conjugated linoleic acid (CLA) which exert aorized reproduction of this article is prohibited.
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Figure 2 Interaction between lipopolysaccharide, hepatic stellate cells and Kupffer cells in the liver
Toll-like receptor-4 (TLR-4) activation by lipopolysaccharide (LPS) downregulates, through the adaptor molecule MyD88, the membrane receptor
Bambi, a pseudoreceptor for TGF-b with negative regulatory function. The removal of this inhibitory pathway leads to stellate cell activation and
secretion of chemotactic factor Ccl2 andCcl4 that recruit circulatingmacrophages to live to form Kupffer cells. Kupffer cells, in turn, secrete TGF-b and
further activate fibrogenetic stellate cells.variety of beneficial biological activities, including inhi-
bitionofcell proliferation, antiatherosclerotic, antidiabetic,
immunomodulatory action and have the ability to reduce
body fat [27]. Lactobacilli and Bifidobacteria from the
mammalian gut, in particular, have been shown to generate
CLA, predominantly the c9,t11 isomer, from free linoleic
acid [28]. Wall et al. [29] found that supplementation
of Bifidobacterium breve to different mammalian species
altered the profile of polyunsaturated fatty acid compo-
sition, resulting in higher intestinal, hepatic and adipose
tissue content of c9,t11 CLA, eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA). These changes were
associated with a reduced expression of proinflammatory
cytokines TNF-a, IL-6 and IFN-g [29].Evidence connecting high-fat diet, gut
microbiota and metabolic disorders in
humans
That differences in the gut microbiota may precede the
development of obesity has been recently shown [30].
Kalliomaki et al. [30] found that Bifidobacterium spp.,
affecting both the quantity and quality of the microbiota
during the first year of life, was higher in number in
children exhibiting a normal weight at 7 years than in
children developing overweight. Conversely, the fecal
content of Staphylococcus aureus was lower in children
remaining lean than in children subsequently becoming
obese. This study suggests that the gut microbiota profileopyright © Lippincott Williams & Wilkins. Unauthoin infancy may impact the risk of subsequent obesity,
although it does not take into account other confounding
factors, such as altered nutrient intake, nor provides a
pathegenetic basis for this association. Creely et al. [31]
found that endotoxemia was two-fold higher in the BMI,
sex, and age-matched type 2 diabetes patients than in
nondiabetic individuals. Furthermore, fasting insulin
levels significantly correlated with LPS concentration
in the nondiabetic population, even after adjustment
for sex, age, and BMI [31]. Interesting data suggest that
high-fat feeding is associated with a higher endotoxemia
in humans. In healthy individuals, a high-fat meal
induces a rapid increase in plasma endotoxemia to con-
centrations that are sufficient to activate cultured human
aortic endothelial cells through the release of soluble
TNF-a from monocytes [32]. A similar metabolic endo-
toxemia was able to increase adipose TNF-a and IL-6
concentrations and insulin resistance in another group of
healthy individuals [33]. These experimental data were
corroborated by a cross-sectional study, in which energy
intake, especially different types of fat intake, was inde-
pendently associated with metabolic endotoxemia in 211
healthy men [34].Molecular mechanisms underlying intestinal
endotoxin absorption
Despite the growing body of evidence connecting gut-
derived LPS to systemic inflammation and metabolicrized reproduction of this article is prohibited.
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intestinal LPS absorption. The observation that a high-
fat diet increases plasma endotoxin levels 2–3-fold higher
than high-carbohydrate diet suggests intestinal fat
absorption and secretion may have a predominant role
in LPS entry into the blood [6].
Using both animal models and cultured enterocytes,
Ghoshal et al. [35] demonstrated that endotoxin is
secreted into the circulation along with the formation
and secretion of chylomicrons. Intragastric lavage with
triolein (which forms chylomicrons) increased plasma
endotoxin, whereas lavage with tributyrin (whose fatty
acids enter the circulation without chylomicron for-
mation) did not. Consistently, polarized CaCo-2 cells
secrete endocytosed endotoxin when incubated with
oleate, which forms chylomicrons, but not when incu-
bated with butyrrate, which does not. Importantly,
inhibiting chylomicron formation blocked the effect of
oleate. These findings suggest endotoxin is transported
into the circulation in conjunction with chylomicron
formation and secretion, not just translocated due to a
breakdown of the intestinal barrier, as previously thought.
If confirmed, these data raise the issue whether inhibit-
ing chylomicron secretion may be effective for treating
metabolic disorders even in the absence of overt hyper-
lipidemia.
Recent experimental data suggest gut microbiota may
interact with the host at least in part through glucagon-
like peptide-2 (GLP-2), a 33-amino acid peptide co-
secreted with GLP-1 from enteroendocrine L cells in
response to carbohydrate and fat ingestion, which has
well known intestinotrophic properties.
Cani et al. [36] assessed changes in the gut microbiota,
intestinal permeability and epithelial tight-junction
proteins ZO-1 and Occludin, hepatic and systemic
inflammation in genetically obese ob/ob mice following
prebiotic or carbohydrate treatment. Prebiotic treated
mice exhibited a lower plasma LPS and cytokines, and
a decreased systemic and hepatic inflammation and oxi-
dative stress, coupled with a lower intestinal permeability
and maintained tight-junction integrity compared to
controls, as expected. These beneficial effects were
associated with an increased gut GLP-2 production, were
abolished by the pretreatment with a GLP-2 antagonist
and were mimicked by the administration of a GLP-2
agonist, thus suggesting GLP-2 may mediate many
benefits of prebiotic treatment. However, to complicate
this scenario, GLP-2 has been shown to increase intes-
tinal lipid absorption and chylomicron production via
CD36 activation, thereby potentially counteracting the
beneficial effects observed with a carbohydrate diet [37].
The net effect of GLP-2 treatment on metabolic and
inflammatory parameters under a high-fat intake, as wellopyright © Lippincott Williams & Wilkins. Unauthas the mechanism(s) through which GLP-2 modulates
intestinal enterocyte lipid and LPS absorption and
secretion, remain poorly understood.Treatment: animal models
Since obesity and high-fat intake are associated with
a shift in the gut microbiota profile, with a relative
reduction in Bifidobacterium spp. and E. rectale/Cl. Coc-
coides, proposed treatments aim at manipulating enteric
flora by using intestinally focused antibiotics, probiotics
(live bacteria given in oral quantities that allow coloniza-
tion of the colon) or prebiotics (nondigestible oligosac-
charides like inulin and oligofructose that are fermented
by colonic microbiota and enhance the growth of beneficial
commensal organisms like Bifidobacterium and Lactoba-
cillus species). Importantly,Bifidobacterium spp. have been
shown to reduce intestinal endotoxin levels and improve
mucosal barrier function in rodents [38,39].
Cani et al. [11] treated ob/ob and high-fat fed mice with
ampicillin and neomycin for 4 weeks. Antibiotic treat-
ment dramatically changed the gut microbiota; reduced
the Lactobacillus spp., Bifidobacterium spp.; and Bacter-
oides-Prevotella spp. All these features were associated
with a strong decrease of metabolic endotoxemia, sys-
temic inflammation, oxidative stress and macrophage
infiltration in the visceral fat. Additionally, insulin resist-
ance and glucose tolerance also significantly improved
with antibiotics. To further demonstrate that the meta-
bolic endotoxemia per se triggered the inflammatory state
in these animals, the authors blocked the endogenous
LPS action by administering an LPS quencher molecule,
inactivating the circulating LPS, or by using a genetic
model of obese mice lacking the LPS receptor CD14, the
double knockout mice ob/ob-CD14-/-. In both models,
impairing the endogenous LPS action restored the
phenotype observed during the antibiotic treatment.
Other experiments using antibiotics or prebiotics obtained
similar results [24,26,36,40–42].Treatment: human data
Few well designed studies assessed the effects of pro-
biotics/prebiotics on different metabolic end-points in
humans.
Cani et al. [43] examined the effects of prebiotics on
satiety and related gut-derived hormones following a test
meal in healthy volunteers. They randomized 10 healthy
adults to either 16 g prebiotics or 16 g dextrin maltose
daily. After 2 weeks, prebiotic treatment increased gut
microbiota fermentation, lowered appetite and improved
postprandial plasma glucose responses. These effects
were accompanied by an increase in plasma glucagon-
like peptide 1 and peptide YY concentrations.orized reproduction of this article is prohibited.
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carbohydrates of an evening meal on glucose tolerance
and related variables at subsequent standardized break-
fast meal in 15 healthy individuals.
They found that the enrichment of indigestible carbo-
hydrates of the evening meal improved glucose tolerance
and adipokine profile at the subsequent breakfast. Such
benefits correlated with the degree of colonic fermenta-
tion as assessed by breath hydrogen test.
Parnell and Reimer [45] examined the effects of oligo-
fructose supplementation on body weight and satiety
hormone concentrations in overweight and obese adults.
They randomized 48 otherwise healthy overweight
adults to 21 g oligofructose or placebo. After 12 weeks,
oligofructose supplementation was associated with
weight loss, reduced caloric intake and improved glucose
tolerance. These changes were associated with reduced
postprandial ghrelin and increased peptide YY responses
Finally, an open-label pilot study assessing the effects of
probiotic VSL#3 in NAFLD was prematurely stopped
because of significant increase in liver fat content after
4 months of treatment, an effect reversed after wash out
of the drug [46].Conclusion
Evidence is growing that the gut microbiota composition
can modulate energy homeostatis and systemic inflam-
mation and may thus contribute to the pathogenesis of
different metabolic disorders.
Experimental models have highlighted several potential
mechanisms at the basis of this association, that is energy
harvest from the diet, regulation of fat storage through
FIAF expression, regulation of lipogenesis and fatty acid
oxidation, regulation of tissue polyunsaturated fatty acid
composition, modulation of innate immune system
activity, modulation of secretion of gut peptides (i.e.
GLP-1, PYY) involved in hunger regulation. Gut micro-
biota manipulation also favorably affected different meta-
bolic disorders in these models. Despite the growing
experimental data, the evidence of effectiveness of these
approaches in humans is still scarce for different reasons.
First, manipulating human intestinal microbiota may be
more difficult in human free-living individuals compared
to standardized laboratory animal models. Second, the
most effective type and dose of prebiotic to treat human
disease are not yet established. Third, the hormonal,
immunomodulatory and metabolic mechanisms under-
lying gut microbiota–host interactions in the intestine,
liver, adipose tissue and inflammatory cells are only lately
being unravelled and may differ between animal models
and humans, among different organs/tissues and amongopyright © Lippincott Williams & Wilkins. Unauthoindividuals with different metabolic milieu. Future
studies need to highlight the molecular basis connecting
gut microbiota to metabolic disorders and to address
potential treatments in well designed trials with adequate
clinical end-points.
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